ROS1 and lung adenocarcinoma: In this retrospective study of 546 lung adenocarcinoma patients with four different driver genes, ROS1 rearrangements were associated with the increased risk of thromboembolic events (TEs), particularly during the peri‐diagnostic period (6 months before and after diagnosis).